// App-Quantinova.ai

294 : Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.

Researchers

Presenter

  • Jennifer Allison

Principal Investigators

  • Natalie Charnley

  • Robert Stevenson

  • Tom Waddell

  • Manon Rhys Pillai

Medical Centers

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Inlyta

  • Methadone hydrochloride

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved